Navigation Links
Study details regulation of vital tumor suppressor gene p53
Date:9/5/2007

(PHILADELPHIA) So vital is the p53 tumor suppressor gene in controlling cancer that its dysfunction is linked to more than half of human cancers. At the same time, the genes capacity for shutting down cell growth, even causing cells to commit suicide if necessary, is so absolute that it must be tightly regulated to maintain the optimal balance between protecting against cancer and permitting normal growth.

Now, a study by scientists at The Wistar Institute reveals new levels of subtlety in the bodys management of this all-important tumor suppressor gene and the protein it produces. The experiments show that, while the addition of a specific molecule at a particular site on the p53 protein prevents it from acting, the addition of a second copy of the same molecule at the same site reverses the effect, sending p53 into action. Further, removal of the second copy returns the protein to its repressed state.

In addition to the implications for understanding the activity of the p53 gene, the findings also outline an important new cycle of gene-regulating modifications involving the addition and removal of the molecules, called methyl groups, that may be widespread in the genome. A report on the study appears in the September 6 issue of Nature.

The p53 tumor suppressor is extremely potent in halting cell growth, says Shelley L. Berger, Ph.D., the Hilary Koprowski Professor at The Wistar Institute and senior author on the study. So, as critical as p53 is in protecting against the unchecked growth of cancer, you dont want it constantly on. If it were always on, your cells wouldnt be able to grow normally. Yet it needs to be constantly on call for activation against cancer and other aberrant cellular developments. Our study shows one way that the cell, working at one particular location on the p53 protein, maintains a nuanced but firm control over the genes activity.

Responsible for tumor suppression throughout the body, the p53 gene
'/>"/>

Contact: Franklin Hoke
hoke@wistar.org
215-898-3716
The Wistar Institute
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Gene study links endometriosis, infertility
2. Study reveals how stress can make you sick
3. Study points out that HIV vaccine may not be accepted easily
4. A new study surpasses Gene Therapy Hurdle
5. Tomato Sauce reduces Cancer Risk- Study
6. A question on study of Adult Stem Cell
7. Study on obesity and heart failure
8. National Lung Study in the process
9. Marijuana gateway theory strengthened by study of twins
10. Old theory of adaptation confirmed by new study
11. Study casts doubt on keyboard ills

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...ng medical device software engineering consulting ... certification. A relatively few medical device so...achieved ISO 13485 certification. Many medical dev... to other ISO standards as well. However, it is so...ing consulting firm to achieve the rigorous qualit...
(Date:12/2/2009)...Newswire/ -- A randomized, controlled study compar...nvasive treatment called percutaneous disc decompr...ile both treatments help patients in the short run...up to two years later. Results of the study, the f...al meeting of the Radiological Society of North Am...
(Date:12/2/2009)...asound of suspicious areas of the breast, includin...ternative to invasive biopsies for women under age...ented today at the annual meeting of the Radiologi...rming high-quality breast ultrasound, we can reduc...iagnostic procedures in young women," said senior ...
(Date:12/1/2009)...ate Christ Medical Center in Oak Lawn, Ill. has be...nter and the first for Chicago’s south and s... hospital’s plans today (December 1) by the ...rd. , Springfield, Ill. (...Lawn, Ill. has become the state’s newest kid...
(Date:12/1/2009)...c. 1 Reportlinker.com announces th...s catalogue: ,, The Future of Monoclonal Antib...hmarking, Product Pipeline and Deals Analysis ,...e-of-Monoclonal-Antibodies---Market-Forecasts-to-2...Deals-Analysis.html ,, Summary ,, The au...
Breaking Medicine News(10 mins):Health News:Medical Device Software Engineering Consulting firm Full Spectrum Software Earns ISO 13485 Certification 2Health News:Outpatient Disc Treatment Gives Long-Term Back Pain Relief 2Health News:Outpatient Disc Treatment Gives Long-Term Back Pain Relief 3Health News:Targeted breast ultrasound can reduce biopsies for women under 40 2Health News:State Approves Plans For Kidney Transplants At Advocate Christ Medical Center 2Health News:State Approves Plans For Kidney Transplants At Advocate Christ Medical Center 3Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 2Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 3Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 4Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 5Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 6Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 7Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 8Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 9Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 10Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 11Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 12Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 13
...ect of hormone replacement therapy may be inhibite...eroidal anti-inflammatory pain killer, report rese...f Pennsylvania. The researchers examined t...coronary heart disease and compared them with 7,00...
...ople another reason to quit smoking, by finding th...oping depression in comparison to those who never...kers who have quit have an elevated risk of depres... style and successful smoking cessation in long ru...
...that vegetarian diet reduces risk of colon cancer ...up as appetizer reduces food intake by about 20 pe...ife factors like choosing your diet regimen or ord...t to find out whether a vegetarian diet is associa...
...lthcare scenario has emerged a heartening developm...ated Paromomycin IM injection manufactured by the...fit drug firm, for inclusion in its Model List for...rasitic disease after malaria. It is a sy...
...ests using gene sequencing is able to help confirm...ns and patients the tools for much more accurate ...e a group of more than 40 inherited and potentiall...ucts that damage organs and tissues. The g...
...t men with chronic gum disease periodontitis, may ...ss of whether they smoke. Periodontitis is...a, though recent evidence suggests the involvement... Roswell Park Cancer Institute, Buffalo. A...
Other Medicine News:Health News:Regular Smokers are at the Risk of Developing Depression 2Health News:Vegetarian Diet Could Reduce Risk of Colon Cancer 2Health News:Vegetarian Diet Could Reduce Risk of Colon Cancer 3Health News:Vegetarian Diet Could Reduce Risk of Colon Cancer 4Health News:A Non-profit Drug Firms Injection to Fight Kala Azar Included in WHOs Model List 2Health News:A Non-profit Drug Firms Injection to Fight Kala Azar Included in WHOs Model List 3Health News:New DNA Tests Advances Treatment of Lysosomal Storage Diseases 2Health News:Men With Chronic Gum Disease at Higher Risk of Tongue Cancer 2
(Date:12/1/2009)..., BELLEVUE, Wash., Dec. 1 /PRNewswire-FirstCall/...g online retailer of health, beauty, vision, and p...y was its best day ever as customer orders were th...the drugstore.com and Beauty.com web stores fe...and their largest gift selection yet. ,, (Logo:...
(Date:12/1/2009)..., NEW YORK, Dec. 1 Reportlinker.... available in its catalogue: ,, Direct to Cons...t and Future Market Outlook, Regulatory Landscape ...om/p0166813/Direct-to-Consumer-DTC-Advertising-in-...k-Regulatory-Landscape-and-Case-Studies.html ,...
(Date:12/1/2009)...ologist reports 90 percent radiation reduction in ...-USNewswire/ -- Dr. James Earls, a radiologist fro...hington, D.C. will present the findings of a study...f radiation heart patients received from CT scans ... Dr. Earls will present the study to the annual me...
Breaking Medicine Technology:drugstore.com, inc. Has Best Day Ever on Cyber Monday 2drugstore.com, inc. Has Best Day Ever on Cyber Monday 3Reportlinker Adds Direct to Consumer (DTC) Advertising in Pharmaceuticals - Current and Future Market Outlook, Regulatory Landscape and Case Studies 2Reportlinker Adds Direct to Consumer (DTC) Advertising in Pharmaceuticals - Current and Future Market Outlook, Regulatory Landscape and Case Studies 3Reportlinker Adds Direct to Consumer (DTC) Advertising in Pharmaceuticals - Current and Future Market Outlook, Regulatory Landscape and Case Studies 4Reportlinker Adds Direct to Consumer (DTC) Advertising in Pharmaceuticals - Current and Future Market Outlook, Regulatory Landscape and Case Studies 5Reportlinker Adds Direct to Consumer (DTC) Advertising in Pharmaceuticals - Current and Future Market Outlook, Regulatory Landscape and Case Studies 6Reportlinker Adds Direct to Consumer (DTC) Advertising in Pharmaceuticals - Current and Future Market Outlook, Regulatory Landscape and Case Studies 7Reportlinker Adds Direct to Consumer (DTC) Advertising in Pharmaceuticals - Current and Future Market Outlook, Regulatory Landscape and Case Studies 8Radiation Reduction in Heart CT Scans Reported in Study 2EGEN Inc Announces the Promotion of Khursheed Anwer Ph D to President and Chief Scientific Officer 12452 1EGEN Inc Announces the Promotion of Khursheed Anwer Ph D to President and Chief Scientific Officer 12452 2GlaxoSmithKline Consumer Healthcare Makes Agency Changes to Support Growth on Global Brands 47821 1GlaxoSmithKline Consumer Healthcare Makes Agency Changes to Support Growth on Global Brands 47821 2Small molecules mimic natural gene regulators 8713 1Small molecules mimic natural gene regulators 8713 2
...ne payment to Pharmasset , , PRINCETON, N.J., Apr...e (Roche SWX: RO, ROG; Pink Sheets: RHHBY) today a...a Phase IIb study of R7128, the nucleoside polymer... treatment of chronic hepatitis C (HCV). The trial...of R7128 in combination with Roche,s PEGASYS(R) (p...
...for Blinatumomab , , NEW YORK, April 24 Micromet...any developing novel, proprietary antibodies for t...e diseases, today held an R&D Day for investor...ork City. , , The presentations highlighted sig...TE antibody platform and included updates on: , ,...
Other Medicine Technology:Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 2Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 3Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 4Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 5Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 6Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 7Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 8Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 9Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 10Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day 2Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day 3Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day 4
PulseOx 7500 Pulse Oximeter
Merlin Patient Care System
Safire Bi-directional Ablation Catheter
VASOVIEW® HemoPro™ Endoscopic Vessel Harvesting System
Medicine Products: